Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole lung lavage followed by inhaled sargramostim for autoimmune pulmonary alveolar proteinosis
2008-007086-23Phase 2Active
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by IRCCS San Matteo Foundation. Primary endpoints: Total resolution of disease, Alveolar-arterial oxygen tension gradient and 4 more. Started Jan 2009; status: active.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on 2008-007086-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007086-23.